AGP Executive Report
Last update: an hour agoHomeopathy & Regulation: India’s AYUSH body warned against calling registered homoeopaths “quacks,” saying it could trigger defamation claims—sparking a fresh censorship-versus-critique debate. Pain Relief Product Push: Blue Scorpion promoted its Caribbean blue scorpion venom homeopathic formula, highlighting dual FDA NDC listings and claims of non-opioid, multi-symptom relief. Pregnancy Safety Watch: A JAMA Pediatrics-linked report raised concerns about acetaminophen use in pregnancy and later child behavior diagnoses, while noting more research is needed. AYUSH Workforce Tensions: Uttarakhand AYUSH doctors launched a phased agitation, starting with black armbands and moving toward an OPD boycott over long-pending administrative demands. Alternative Care in the Spotlight: A Sri Lankan doctor in Perth was convicted of indecent assault during an acupuncture appointment, renewing scrutiny on practitioner conduct. Wellness Community Moves: A new Afrocentric boutique at Northtown Mall will fund maternal health programs and offer free group acupuncture massages and meditation sessions. Sleep & Stress Trends: A piece on color noise for sleep and another on contrast therapy at a London banya reflect ongoing demand for non-drug relaxation tools. Ayurveda Market Growth: A market forecast projects Ayurveda could reach $107.62B by 2035, driven by plant-based wellness, regulation, and e-commerce.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
